ABSTRACT
This chapter presents a trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interaction of Pentobarbital. Although approved for the symptomatic management of acute anxiety, the barbiturates, including pentobarbital, generally have been replaced by the benzodiazepines for this indication because of their greater efficacy and lower toxicity. If pentobarbital pharmacotherapy is required, breast-feeding probably should be discontinued. If desired, lactation may be maintained and breast-feeding resumed following the discontinuation of short-term pentobarbital pharmacotherapy. Intramuscular, oral, and rectal pentobarbital pharmacotherapy may be prescribed according to individual patient needs. Intramuscular pharmacotherapy provides a precise dosage and a rapid onset of hypnotic action. Emergency respiratory supportive equipment and medical personnel must be immediately available for patients who require intravenous pentobarbital pharmacotherapy.
